Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) had its price objective lowered by HC Wainwright from $14.00 to $11.00 ...

CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage ...

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have ...

Fintel reports that on January 10, 2025, Roth MKM initiated coverage of Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) with a Buy recommendation. Analyst Price Forecast Suggests 729.09% Upside As of ...

Trading Recap. On Friday, Reviva Pharmaceuticals Holdings Inc (RVPH) stock saw a modest uptick, ending the day at $1.88 which repr ...

In recent trading, Reviva Pharmaceuticals Holdings Inc (RVPH) stock price has shown some volatility, fluctuating -19.80% over the last ...

Fintel reports that on January 10, 2025, Maxim Group upgraded their outlook for Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) from Hold to Buy. Analyst Price Forecast Suggests 724.68% Upside As ...

H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $11 from $14 and keeps a Buy rating on the shares. Johnson ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens ...

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory ...